Repatha Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The repatha market research report is one of a series of new reports that provides repatha market statistics, including the repatha industry global market size, regional shares, competitors with the repatha market share, detailed repatha market segments, market trends, and opportunities, and any further data you may need to thrive in the repatha industry. This repatha market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The growth in the forecast period can be attributed to healthcare shifts towards personalized treatment, expanding healthcare access, rising focus on preventing cardiovascular events, expanding role of telemedicine, and rising investment in cardiovascular research. Major trends in the forecast period include advancements in monoclonal antibody technology, innovations in drug delivery systems, integration with digital health platforms, introduction of combination therapies, and development of long-acting formulations.

The increasing prevalence of cardiovascular diseases is expected to drive the growth of the repatha market in the future. Cardiovascular diseases (CVDs) include conditions that affect the heart and blood vessels, such as coronary artery disease, heart attacks, strokes, and hypertension. The rise in cardiovascular diseases is linked to factors such as poor diet, lack of exercise, smoking, excessive alcohol consumption, high blood pressure, and genetic factors. Repatha (evolocumab) helps treat these diseases by lowering LDL cholesterol levels, reducing the risk of heart attacks, strokes, and other cardiovascular events in patients with high cholesterol or atherosclerotic cardiovascular disease. For example, the British Heart Foundation reported in September 2024 that about 7.6 million individuals in the UK are currently affected by heart and circulatory diseases, with projections suggesting an increase of 1 to 2 million more people by 2040. This growing prevalence of cardiovascular diseases is expected to boost the demand for repatha.

The growing prevalence of high cholesterol is also expected to fuel the growth of the repatha market. High cholesterol refers to elevated levels of LDL cholesterol in the blood, which increases the risk of cardiovascular diseases such as heart attacks, strokes, and coronary artery disease. Factors such as poor diet, lack of physical activity, genetics, obesity, smoking, and excessive alcohol consumption contribute to the rise in high cholesterol. Repatha (evolocumab) works by inhibiting a protein called PCSK9, which enhances the liver's ability to remove LDL cholesterol from the bloodstream, significantly lowering cholesterol levels. For instance, according to the Australian Bureau of Statistics in December 2023, about 8.4% of people, or 2.1 million individuals, in Australia reported having high cholesterol in 2022. As the prevalence of high cholesterol continues to rise, the demand for repatha is also expected to grow.

The rising obesity rate is expected to accelerate the growth of the repatha market. Obesity, defined by a body mass index (BMI) that classifies individuals as obese, is increasingly prevalent due to factors such as poor diet, increased consumption of high-calorie foods, sedentary lifestyles, lack of physical activity, and genetics. Repatha is being explored as a treatment option for obesity by helping to reduce cholesterol levels and improve metabolic health, though it is primarily used for managing hyperlipidemia. The Centers for Disease Control and Prevention (CDC) reported in September 2023 that in 2022, 22 states in the US had an adult obesity rate of 35% or greater, up from 19 states in 2021. This rising obesity rate is expected to further drive the growth of the repatha market.

The key company operating in the repatha market is Amgen Inc.

North America was the largest region in the repatha market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in repatha report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the repatha market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Repatha (evolocumab) is a monoclonal antibody used to lower cholesterol levels in patients with hyperlipidemia. It works by inhibiting PCSK9, a protein that reduces the liver's ability to clear LDL cholesterol from the bloodstream. Repatha is typically prescribed for individuals who cannot reach their target cholesterol levels through diet or statin therapy alone.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary indications for Repatha include primary hypercholesterolemia, homozygous familial hypercholesterolemia (FH), and atherosclerotic cardiovascular disease (CVD). Primary hypercholesterolemia refers to elevated blood cholesterol levels, often due to genetic or lifestyle factors, which increase the risk of cardiovascular disease. Repatha is distributed through various channels, including hospital pharmacies, retail pharmacies, and online platforms, and is used by a wide range of patients, including pediatric, adult, and geriatric populations.

The repatha market consists of sales of repatha injections and repatha pre-filled pens. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.